A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab-Reference-Cited by-同舟云学术

A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

Published:2017-02-21 Issue:2 Volume:177 Page:243-253
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Sawas Ahmed¹,Farber Charles M.²,Schreeder Marshall T.³,Khalil Mazen Y.⁴,Mahadevan Daruka⁵,Deng Changchun¹,Amengual Jennifer E.¹,Nikolinakos Petros G.⁶,Kolesar Jill M.⁷,Kuhn John G.⁸,Sportelli Peter⁹,Miskin Hari P.⁹,O'Connor Owen A.¹

Affiliation:

1. Center for Lymphoid Malignancies; Columbia University Medical Center; New York NY USA

2. Carol G. Simon Cancer Center; Morristown NJ USA

3. Clearview Cancer Institute; Huntsville AL USA

4. St. Bernards Clopton Clinic; Jonesboro AR USA

5. The West Clinic; Memphis TN USA

6. University Cancer and Blood Center; Athens GA USA

7. Carbone Comprehensive Cancer Center; University of Wisconsin; Madison WI USA

8. University of Texas Health Science Center at San Antonio; San Antonio TX USA

9. TG Therapeutics Inc.; New York NY USA

Funder

TG Therapeutics, Inc

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14534/fullpdf

Reference46 articles.

1. Comparison of cell lysis mediated by LFB-R603 (ublituximab) with that mediated by ofatumumab against cells expressing low levels of CD20. [Abstract];Bellon;Blood,2011

2. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes;Beum;The Journal of Immunology,2006

3. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab;Bowles;Blood,2006

4. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia;Burger;New England Journal of Medicine,2015

5. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study;Cartron;Blood,2014

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment;Bioactive Materials;2024-12

2. Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling;Antibodies;2024-07-09

3. Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy;Drug Design, Development and Therapy;2024-07

4. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability;Drugs;2024-03

5. Pharmacology to Practice;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21